USNA vs. CGC, CRON, MNMD, BTMD, ACB, CDXC, TYRA, DH, AORT, and AVNS
Should you be buying USANA Health Sciences stock or one of its competitors? The main competitors of USANA Health Sciences include Canopy Growth (CGC), Cronos Group (CRON), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), Tyra Biosciences (TYRA), Definitive Healthcare (DH), Artivion (AORT), and Avanos Medical (AVNS). These companies are all part of the "medical" sector.
Canopy Growth (NASDAQ:CGC) and USANA Health Sciences (NYSE:USNA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership.
3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are held by institutional investors. 0.4% of Canopy Growth shares are held by insiders. Comparatively, 0.3% of USANA Health Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Canopy Growth has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
Canopy Growth presently has a consensus price target of $4.87, suggesting a potential downside of 67.29%. USANA Health Sciences has a consensus price target of $48.00, suggesting a potential upside of 15.66%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts clearly believe USANA Health Sciences is more favorable than Canopy Growth.
In the previous week, USANA Health Sciences had 1 more articles in the media than Canopy Growth. MarketBeat recorded 17 mentions for USANA Health Sciences and 16 mentions for Canopy Growth. USANA Health Sciences' average media sentiment score of 0.97 beat Canopy Growth's score of 0.21 indicating that Canopy Growth is being referred to more favorably in the media.
USANA Health Sciences has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
USANA Health Sciences has a net margin of 6.93% compared to USANA Health Sciences' net margin of -326.75%. Canopy Growth's return on equity of 13.49% beat USANA Health Sciences' return on equity.
USANA Health Sciences received 375 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 60.77% of users gave USANA Health Sciences an outperform vote while only 19.80% of users gave Canopy Growth an outperform vote.
Summary
USANA Health Sciences beats Canopy Growth on 14 of the 18 factors compared between the two stocks.
Get USANA Health Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding USNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
USANA Health Sciences Competitors List
Related Companies and Tools
